Immunoscintigraphy of local recurrent rectal cancer with 99mTc-labeled anti-CEA monoclonal antibody CL58

Table 1 Surgical procedure, serum CEA level and immun-oscintigraphy data

Patients	Gender	Operation LAR/APR*	RII result	Serum CEA level
1	M	LAR	+	16.4
2	F	LAR	+	25.4
3	M	APR	+	25.4
4	M	LAR	+	16.4
5	M	LAR	+	13.3
6	M	LAR	+	2.1
7	F	APR	+	23.9
8	F	LAR	-	0.9
9	M	LAR	+	8.2
10	M	LAR	+	6.0
11	M	APR	+	52.8
12	F	APR	+	9.0
13	M	LAR	+	50.0
14	F	LAR	+	52.0
15	F	LAR	+	500.0
16	M	LAR	+	33.9
17	F	LAR	+	317.7
18	M	APR	+	51.8
19	M	APR	+	68.7
20	F	LAR	+	17.9
21	M	APR	+	14.5
22	F	APR	+	27.5
23	M	APR	+	34.2
24	M	APR	+	6.8
25	F	LAR	+	8.9
26	M	LAR	+	1.0
27	F	APR	+	7.5
28	F	LAR	+	6.1
29	M	LAR	+	13.7
30	F	LAR	-	1.3
31	M	LAR	+	24.9
32	F	LAR	-	7.7
33	F	APR	-	2.4
34	M	LAR	+	13.0
35	M	LAR	-	1.5
36	F	LAR	+	14.0

Table 2 Sites of local recurrence

Patients	Gender	Operation LAR/APR*	RII(+/-)	CEA(+/-)	Parabladder	Presacral	Colon	Perineal
1	M	LAR	+	16.4	+	+	-	-
2	F	LAR	+	25.4	+	-	-	-
3	M	APR	+	25.4	-	+	-	-
4	M	LAR	+	16.4	+	+	-	-
5	M	LAR	+	13.3	+	-	-	-
6	M	LAR	+	2.1	+	+	-	-
7	F	APR	+	23.9	-	+	+	-
9	M	LAR	+	8.2	+	-	-	-
10	M	LAR	+	6.0	-	+	-	-
11	M	APR	+	52.8	+	-	-	-
12	F	APR	+	9.0	-	+	-	-
13	M	LAR	+	50.0	-	-	-	-
14	F	LAR	+	52.0	+	-	-	-
15	F	LAR	+	500.0	+	+	-	-
16	M	LAR	+	33.9	+	-	-	+
17	F	LAR	+	317.7	+	-	-	-
18	M	APR	+	51.8	-	-	-	-
19	M	APR	+	68.7	+	-	-	-
20	F	LAR	+	17.9	+	+	-	+
21	M	APR	+	14.5	+	-	-	-
22	F	APR	+	27.5	-	-	-	-
23	M	APR	+	34.2	-	+	-	-
24	M	APR	+	6.8	-	+	-	+
25	F	LAR	+	8.9	+	+	-	-
26	M	LAR	+	1.0	+	-	-	-
27	F	APR	+	36.2	-	-	-	-
28	F	LAR	+	6.1	+	-	+	-
29	M	LAR	+	13.7	+	+	-	-
31	M	LAR	+	24.9	+	+	-	-
34	M	LAR	+	13.0	-	-	-	-
36	F	LAR	+	14.0	+	+	-	-

Table 3 Distant metastases

Patients	Gender	Operation LAR/APR*	CEA(+/-)	Liver	Sternum	RPLN	FAC	Lung	Parastoma
1	M	LAR	16.4	-	-	-	-	-	-
2	F	LAR	25.4	-	-	-	-	+	-
3	M	APR	25.4	-	-	-	-	-	-
4	M	LAR	16.4	-	-	-	-	-	-
5	M	LAR	13.3	-	-	-	-	-	-
6	M	LAR	2.1	-	-	-	-	+	-
7	F	APR	23.9	-	-	-	-	-	-
9	M	LAR	8.2	-	-	-	-	-	-
10	M	LAR	6.0	-	-	-	-	-	-
11	M	APR	52.8	-	-	-	-	-	-
12	F	APR	9.0	-	-	-	-	-	-
13	M	LAR	50.0	-	+	-	-	-	-
14	F	LAR	52.0	-	-	-	-	-	-
15	F	LAR	500.0	-	-	-	-	+	-
16	M	LAR	33.9	-	-	-	-	-	-
17	F	LAR	317.7	-	-	+	-	-	-
18	M	APR	51.8	-	-	-	+	-	-
19	M	APR	68.7	-	-	-	-	-	-
20	F	LAR	17.9	-	-	-	-	-	-
21	M	APR	14.5	-	-	-	-	-	-
22	F	APR	27.5	-	-	-	-	-	+
23	M	APR	34.2	-	-	-	-	-	-
24	M	APR	6.8	-	-	-	-	-	-
25	F	LAR	8.9	-	-	-	-	-	-
26	M	LAR	1.0	-	-	-	-	-	-
27	F	APR	36.2	+	-	-	-	-	-
28	F	LAR	6.1	-	-	-	-	-	-
29	M	LAR	13.7	-	-	-	-	-	-
31	M	LAR	24.9	-	-	-	-	-	-
34	M	LAR	13.0	-	+	-	-	+	-
36	F	LAR	14.0	-	-	-	-	-	-

RPLN: Retroperitoneal lymph nodes; FAC: Free abdominal cavity.

Table 4 Immunoscintigraphy following APR

Patients	Gender	Operation LAR/APR*	Path(+/-)	CEA(+/-)	Parabladder	Presacral	Colon	Perineal	Liver	Sternum	RPLN	FAC	Lung	Parastoma
3	M	APR	Puncture	25.4	-	+	-	-	-	-	-	-	-	-
7	F	APR	LTS	23.9	-	+	+	-	-	-	-	-	-	-
11	M	APR	Puncture	52.8	+	-	-	-	-	-	-	-	-	-
12	F	APR	FTG	9.0	-	+	-	-	-	-	-	-	-	-
18	M	APR	Puncture	51.8	-	-	-	-	-	-	-	+	-	-
19	M	APR	Puncture	68.7	+	-	-	-	-	-	-	-	-	-
21	M	APR	Puncture	14.5	+	-	-	-	-	-	-	-	-	-
22	F	APR	Puncture	27.5	+	-	-	-	-	-	-	-	-	-
23	M	APR	LTS	34.2	-	+	-	-	-	-	-	-	-	-
24	M	APR	FTG	6.8	-	+	-	+	-	-	-	-	-	-
27	F	APR	Puncture	36.2	-	-	-	-	+	-	-	-	-	-

Puncture: Biopsy and pathological examination; LTS: Local tissue smear tumors invaded skin; FTG: Further tumor growth.